A Phase II/III European trial of Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (aGvHD) with lower gastrointestinal involvement .

Trial Profile

A Phase II/III European trial of Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (aGvHD) with lower gastrointestinal involvement .

Planning
Phase of Trial: Phase II/III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 According to a Kamada media release, the company anticipate submission of Clinical Trial Application for alpha-1 antitrypsin IV for graft-versus-host disease in Europe in second half of 2017.
    • 31 Jan 2017 New trial record
    • 23 Jan 2017 According to a Kamada media release, the guidance received from the EMA was based on design of the U.S. Phase 2/3 trial (see profile 278532).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top